Nexstim Plc · OMXHEX:NXTMH
Nexstim — FY2014 Earnings Presentation
15 slides from Nexstim's earnings presentation, Feb 26, 2015
Slide 1: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Janne Huhtala | CEO | Nexstim Plc Mikko Karvinen | CFO | Nexstim Plc Financial Results 2014 – Feb 26 2015
Slide 2: Important information
Important information This document and the information contained herein are being presented by Nexstim Oyj FORWARD-LOOKING STATEMENTS (“Nexstim” or the “Company”). In connection with any presentation or review of this This document may contain forward-looking statements that reflect the Company’s c
Slide 3: Nexstim – Targeting a paradigm shift in stroke rehabilitation
Introduction Nexstim – Targeting a paradigm shift in stroke rehabilitation • World-leading medical technology and software with game changing potential in stroke rehabilitation Nexstim’s Navigated Nexstim’s NavigatedBrain Therapy® Brain (NBT) Therapy® Targeting Targetingaablockbuster blockbustermark
Slide 4: Company Highlights, July – December 2014
Financial Statement Release 2014 Company Highlights, July – December 2014 ● Phase III multi-centre trial in the US for stroke therapy is progressing according to plans, first milestone interim analysis from the Phase III stroke therapy trial expected in Q3 2015 ● Successful listing of the company’s
Slide 5: Technology platform applied in stroke and brain surgery
Introduction Technology platform applied in stroke and brain surgery Novel technology Two products Main uses Status Navigation technology to Stroke rehabilitation –CE marked deliver accurate magnetic Navigated Precise localisation of the –Positive Phase II data pulses to stimulate the Brain correct
Slide 6: NBT for stroke rehabilitation – How it works
Stroke – NBT® System NBT® for stroke rehabilitation – How it works Problem post stroke: Nexstim’ssolution: Overactive inhibition from the non-damaged side interferes Repeated inhibitory stimulation to non-damaged side when the patient tries to move paralyzed limb restores balance, removing barriers
Slide 7: Efficacy demonstrated in Phase II trial
Stroke – NBT® System Efficacy demonstrated in Phase II trial Change in upper extremity Fugl-Meyer score from baseline Trial outcome: Absolute average improvement of 20 13.8 Fugl-Meyer scores 15 P<0.05 = difference of "holding an object" and "buttoning a shirt" 84% responder rate (above "MCID" for NB
Slide 8: Nexstim's unique technology provides distinct benefits
Stroke – NBT® System Nexstim’s unique technology provides distinct benefits Integration of TMS and navigation Several distinct benefits Enhanced limb move ● TMS-navigation integration: ● Improved accuracy: Accurate ● Substantially Nexstim combines non-invasive localisation of the target muscle impro
Slide 9: Phase III trial - Laying the groundwork for commercialisation
Stroke – NBT® System Phase III trial - Laying the groundwork for commercialisation Study in brief Study goals Conducted at 12 top US rehab sites Rehabilitation Institute of Chicago (central site) ● Document ● Establish clinical efficacy of NBT® in TIRR Memorial Hermann Hospital (Houston) effects/eff
Slide 10: Status of Clinical Development
Financial Statement Release 2014 Status of Clinical Development ● The clinical Phase III multi-centre trial is progressing according to plans. The next interim analysis milestones are estimated to be reached Q3 2015 and Q1 2016 and the clinical evidence is assumed to be ready by the end of 2016 ● In
Slide 11: Highlights in Stroke Rehabilitation (NBT)
Stroke – NBT® System Highlights in Stroke Rehabilitation (NBT®) – 2.1m strokes each year in the US and Europe Huge unmet need – Stroke is the leading cause of long-term disability in Western world – While current standard treatment of physical/occupational therapy is not very Few effective alternati
Slide 12: IP position
Patents IP position 61 granted patents 70 pending patents Right to software: Nexstim owns rights to its NBT® and NBS Systems’ e-field based navigation software developed Creating hurdles for competitors: by e.g. seeking patent protection on different parts of the products and making it more difficul
Slide 13: Key Performance Indicators
Financial Statement Release 2014 Key Performance Indicators EUR in thousands H2 2014 H2 2013 FY 2014 FY 2013 6 months 6 months 12 months 12 months Net sales 1,796.5 1,371.7 2,210.4 1,871.0 Personnel expenses -2,018.3 -1,492.5 -3,660.2 -3,043.4 Depreciation and amortisation -252.1 -96.0 -377.4 -237.7
Slide 14: Summary and Outlook
Financial Statement Release 2014 Summary and Outlook ● World-leading medical technology and software with game changing potential in stroke rehabilitation ● Good progress since IPO – business on track ● Based on its business forecast and sensitivity analysis the company expects its net sales from th
Slide 15: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation